Navigation Links
Experimental Staph Vaccine Fails to Work, Study Finds
Date:4/2/2013

TUESDAY, April 2 (HealthDay News) -- An experimental vaccine does not reduce the risk of staph infections in patients who have had heart or chest surgery, a large new study finds.

The study included more than 7,000 thousand adult cardiothoracic patients. About half of them received an injection of the "V710" vaccine 14 to 60 days before their surgery, while the others received a placebo.

At 90 days after surgery, Staphylococcus aureus infections showed up in 22 of 3,528 vaccinated patients and in 27 of 3,517 patients who received the placebo. No significant differences in effectiveness were ever seen between the vaccine and placebo groups during the study.

The researchers also found that patients who received the vaccine had more negative side effects in the 14 days after vaccination than those who received the placebo (31 percent vs. 22 percent), including serious problems (1.7 percent vs. 1.3 percent).

In addition, patients who received the vaccine were much more likely to suffer multi-organ failure at some point in the study (31 vs. 17 events), according to the study in the April 3 issue of the Journal of the American Medical Association.

The difference in the death rate from all causes was not statistically significant between the groups of patients (201 of 3,958 vs. 177 of 3,967), but the death rate among patients who developed staph infections was much higher among those who received the vaccine (15 of 73 vs. 4 of 96), according to a journal news release.

"These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions," concluded Dr. Vance Fowler Jr., of Duke University Medical Center, and colleagues.

Dr. Preeti Malani, of the University of Michigan Health System, wrote an accompanying journal editorial.

"While the prevention of S. aureus infections should remain a priority for future investigation, novel approaches must move beyond vaccine strategies -- and for that matter, beyond S. aureus. Even if a viable staphylococcal vaccine were to be developed, this would not address non-S. aureus infections," Malani wrote.

More information

The U.S. Centers for Disease Control and Prevention discusses surgical site infections.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, April 2, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug May Work Against Hepatitis C
2. Experimental Alzheimers Drug Shows Promise, Study Finds
3. Experimental Vitiligo Treatment Shows Promise in Mice
4. Harmful effects of bisphenol A proved experimentally
5. Experimental agent briefly eases depression rapidly in test
6. NIH-funded trial launched to assess experimental TB drug
7. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
8. Experimental Antidepressant Appears Quick-Acting, Safe
9. More than a third of high-risk leukemia patients respond to an experimental new drug
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Experimental Insomnia Drug Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Staph Vaccine Fails to Work, Study Finds
(Date:1/24/2017)... ... January 24, 2017 , ... Element Blue ™, a ... a strategic partnership with Lucidworks , the company transforming the way people ... platform for building powerful enterprise search applications. , Element Blue is a global ...
(Date:1/24/2017)... ... January 24, 2017 , ... Manzo Pharmaceuticals, LLC., announced ... Registered Trademark by the United States Patent and Trademark Office. The purpose ... confuse consumers into thinking that other products are similar to the patented Lacto-Freedom ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under ... year in 2017. The entrepreneurs will showcase their businesses on February 6, 2017, ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... it has officially formed a distribution partnership with Byers Scientific & Manufacturing ... management industry. , Through the agreement, OMI Industries formulated a special version of ...
(Date:1/24/2017)... Rancho Santa Margarita, CA (PRWEB) , ... January 24, 2017 , ... ... career advancement platform for 21st century leadership, has named Hector M. Chavez, Manager, Employee ... cancer and diabetes treatment center - as its Hispanic Leader of the Month. City ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Market Research Future has a half cooked research report on global ... Surgery & Integumentary System is growing rapidly and expected to reach ... Market Highlights ... Global Plastic Surgery & Integumentary System Market has been evaluated as ... high growth figures and thriving in the coming future. There has ...
(Date:1/24/2017)... -- Analysis of the Liquid Biopsy Market by Sample ... our new study reveals trends, R&D progress, and predicted revenues ... in this sector you must read this brand new report. ... assessing data, trends, opportunities and business prospects there. ... Discover How to Stay Ahead ...
(Date:1/24/2017)... SAN DIEGO , Jan. 24, 2017 /PRNewswire/ ... leader in clinical materials management services, is pleased ... Director of Operations. Kevin joins the Sherpa team ... to the highest level of service excellence. ... supply chain and pharmaceutical manufacturing industries. He has ...
Breaking Medicine Technology: